RESEARCH ARTICLE

An Updated Meta-Analysis of Randomized Controlled Trials Assessing the Effect of Sorafenib in Advanced Hepatocellular Carcinoma

Songlin Peng, Yang Zhao, Feng Xu, Changjun Jia, Yongqing Xu, Chaoliu Dai*

Department of Hepatobiliary Surgery, The Affiliated Shengjing Hospital of China Medical University, Shenyang 110004, China

*daicl@sj-hospital.org

Abstract

Background: The efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and safety of sorafenib for treating patients with advanced HCC.

Methods: The PubMed, Embase, and Web of Science databases were searched. Eligible studies were randomized controlled trials (RCTs) that assessed sorafenib therapy in patients with advanced HCC. The outcomes included overall survival (OS), time to progression (TTP), overall response rate (ORR), and toxicities. Hazard ratio (HR) and risk ratio (RR) were used for the meta-analysis and were expressed with 95% confidence intervals (CIs).

Results: Seven RCTs, with a total of 3807 patients, were included in this meta-analysis. All patients received sorafenib alone, or with other chemotherapeutic regimens. Pooled estimates showed that sorafenib improved the OS (HR = 0.74, 95% CI: 0.61, 0.90; P = 0.002), or TTP outcomes (HR = 0.69, 95% CI: 0.55, 0.86; P = 0.001). Subgroup analysis revealed that sorafenib was more effective in the patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1–2 (HR = 0.77, 95% CI: 0.60, 1.0; P = 0.05), or macroscopic vascular invasion (MVI), and/or extrahepatic spread (EHS) (HR = 0.65, 95% CI: 0.46, 0.93; P = 0.02), in terms of OS. Patients who received sorafenib did not have a higher ORR (RR = 0.85, 95% CI: 0.65, 1.11; P = 0.10). In addition, there was a slight increase in toxicity in the sorafenib group.

Conclusion: Treatment with sorafenib significantly improved OS and TTP in patients with advanced HCC. Additional large-scale, well-designed RCTs are
needed to evaluate the efficacy of sorafenib-based therapy in the treatment of advanced HCC.

**Introduction**

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths among men and the sixth among women [1]. In the west, approximately 30–40% of all HCC patients are diagnosed at an early stage, and might benefit from curative treatments [2, 3], such as partial hepatectomy, radiofrequency ablation (RFA), and percutaneous ethanol injection (PEI). For patients who undergo these procedures, five-year survival rates of 60–70% can be achieved in selected patients [4]. Patients diagnosed at an intermediate stage may obtain limited survival benefit from transarterial chemoembolization (TACE); however, most patients progress to an advanced stage after the initial therapeutic benefit.

Sorafenib is a multi-target tyrosine kinase inhibitor. It acts by blocking the activities of the serine-threonine kinases Raf-1 and B-Raf, and the receptor tyrosine kinases of the vascular endothelial growth factor receptors [5–7], consequently inhibiting tumor-cell proliferation and tumor angiogenesis [5, 6, 8]. Results from the randomized, placebo-controlled phase-3 Sorafenib HCC Assessment Randomized Protocol (SHARP) trial in patients with advanced HCC showed that treatment with sorafenib could significantly prolong overall survival (OS) and time to progression (TTP) [9], and that sorafenib-associated adverse events were tolerable. Median OS in the sorafenib and placebo groups was 10.7 and 7.9 months, respectively, while median time to progression (TTP) was 5.5 and 2.8 months, respectively [9]. Positive outcomes of sorafenib therapy were also observed in the phase-3 Sorafenib Asia-Pacific trial, which was conducted in China, South Korea, and Taiwan [10]; these trials confirmed the benefits of sorafenib therapy in patients with advanced HCC.

However, baseline characteristics may affect the therapeutic efficacy of sorafenib therapy. Patients with differences in disease etiology, tumor burden, Eastern Cooperative Oncology Group performance status (ECOG PS), and the Barcelona Clinic Liver Cancer (BCLC) tumor stage, may respond differently to sorafenib treatment. To identify whether baseline patient characteristics affect the efficacy and safety of sorafenib in the treatment of advanced HCC, we performed a comprehensive meta-analysis to evaluate its effect in general, and in specific subpopulations.
Methods and Materials

Literature research and inclusion criteria

We conducted a comprehensive literature search of the PubMed, Embase, and Web of Science databases to recover all relevant records published up to March 16, 2014. The following search items were used: ("sorafenib"[Supplementary Concept] OR "sorafenib"[All Fields]) AND ("carcinoma, hepatocellular"[MeSH Terms] OR ("carcinoma"[All Fields] AND "hepatocellular"[All Fields]) OR "hepatocellular carcinoma"[All Fields] OR ("hepatocellular"[All Fields] AND "carcinoma"[All Fields])). The search was limited to human subjects and randomized controlled trials (RCTs). No language limitations were imposed. We also manually searched the reference lists of RCTs until no additional eligible trials could be identified. Studies that met the following inclusive criteria were considered eligible for this meta-analysis: (1) study design: RCT; (2) study population: adult patients with advanced (unresectable or metastatic) HCC; adequate renal, cardiac, and hematologic function; and a life expectancy of 12 weeks or more; (3) study intervention: patients in the treatment arm received sorafenib or sorafenib-based therapy, whereas patients in the control arm received placebo or placebo-based (without sorafenib) therapy; (4) outcome measures: OS was the primary outcome measure; the secondary outcomes included TTP, ORR, and toxicity.

Data extraction and quality assessment

Two investigators (Peng and Dai) independently extracted the following data from each study: first author, year of publication, number of patients (intervention/control), performance status, treatment regimen, OS, TTP, ORR, and toxicity. A standardized Excel file was established to collate the data. In case the same trial appeared in different publications, we only chose the most informative article to avoid duplication of information. Disagreements were resolved through discussion and consensus.

The methodological quality of each study was assessed with the Jadad scale [11]. The scale evaluates three criteria, which include randomization (0–2 points), blinding (0–2 points), and dropouts and withdrawals (0–1 point) in the RCT study. A score of 1 point is assigned when a criterion is appropriately described. The scale ranges from 0 to 5 points; studies with a score ≥3 points are considered to be of high quality [12].

Statistical analyses

All outcomes were expressed in terms of hazard ratio (HR), risk ratio (RR), and 95% confidence intervals (CIs). The heterogeneity of studies was assessed with Cochran’s Q chi-square test and I^2 analysis. Studies with a P value <0.1 or I^2>50% [13] were considered to have heterogeneity. A fixed-effects model [14] or random-effects model [15] was used to pool the estimates, depending on the absence or presence of heterogeneity. When considerable heterogeneity was
present, sensitivity analyses were conducted to identify potential sources. Publication bias was assessed by using the Begg and Egger tests [16, 17]. In some studies, Kaplan-Meier curves were provided instead of HR and 95% CI; in these cases, we used the method described by Tierney to estimate the HR and 95% CI from the Kaplan-Meier curves [18]. A P value <0.05 was judged as statistically significant, except where otherwise specified. All analyses were performed with STATA, version 12.0 (Stata Corporation, College Station, TX, USA).

Results

Identification of eligible studies

The initial database search yielded 324 studies, of which 53 were excluded for duplicate records, and 234 were excluded for various reasons based on the titles/abstracts (Figure 1). The remaining 37 studies were considered for full-text review, of which, the following studies were excluded: two were eliminated as they did not provide any outcomes of interest [19, 20], one assigned sorafenib in both arms [21], seven were single-arm trials [22–28], and one included patients who received sorafenib after TACE [29]. Finally, seven RCTs met the inclusion criteria, and were included in this analysis [9, 10, 30–34].

Study characteristics and quality assessment

The main characteristics of the seven RCTs included in this meta-analysis are presented in Table 1. All studies were selected strictly based on prior inclusion criteria. The studies were published between 2008 and 2013. The size of the RCTs ranged from 52 to 1155 patients (total of 3807 patients). The clinical characteristics were well matched for gender, age, status, and stage. Patients in these studies were from Europe, the Americas, Australia, Asia and Africa. The predominant reasons for liver disease were hepatitis C virus infection (44.1%), followed by hepatitis B virus infection (37.7%), and alcohol consumption (14.3%). Approximately 72% of the patients were graded as BCLC stage C, which indicated advanced HCC. Sorafenib was administered alone, or in combination with other chemotherapeutic agents. The dosage and schedule of sorafenib was the one approved by the PDA (400 mg PO twice daily) in each trial. The median Jadad score of the included studies was 4 (range from 4 to 5).

Overall survival

All the included studies reported the OS data [9, 10, 30–34]. The aggregated results suggested that sorafenib was associated with a significant improvement in OS (HR=0.74, 95% CI: 0.61, 0.90; P=0.002) (Figure 2). The test for heterogeneity was significant (P=0.000, $I^2=77.0\%$). Subsequently, we conducted subgroup analysis to explore potential sources of heterogeneity. The results revealed that sorafenib was an effective treatment for patients with ECOG PS of 1–2 (HR=0.77, 95% CI: 0.60, 1.0; P=0.05), or macroscopic vascular invasion (MVI) and/or
extrahepatic spread (EHS) (HR = 0.65, 95% CI: 0.46, 0.93; P = 0.02) (Table 2). The Begg and Egger tests provided no evidence of publication bias (for Begg’s test, Z = 0.75, P = 0.453; for Egger’s test, t = 0.28, P = 0.792).

Time to progression

Six studies reported the data in terms of TTP [9, 10, 30–33]. The pooled estimates using a random-effects model showed that, in advanced HCC, a TTP benefit existed in the sorafenib group when compared with the control group (HR = 0.69, 95% CI: 0.55, 0.86; P = 0.001) (Figure 3). The test for heterogeneity was significant (P = 0.000, I² = 84.4%). Subsequently, we conducted subgroup analysis to explore potential sources of heterogeneity. The results showed significant TTP benefits of sorafenib treatment in the patients irrespective of MVI, EHS, and ECOG status (Table 2). The Begg and Egger tests provided no evidence of publication bias (for Begg’s test, Z = 0.19, P = 0.851; for Egger’s test, t = 1.06, P = 0.349).
Overall response rate

Five studies reported data for ORR [30–34]. The pooled results showed that patients treated with sorafenib did not have a higher ORR when compared with other treatments (RR = 0.85, 95% CI: 0.65, 1.11; P = 0.10) (Figure 4). The Begg and Egger tests provided no evidence of publication bias (for Begg’s test, Z = 0.73, P = 0.462; for Egger’s test, t = 2.01, P = 0.249).

Adverse events

Five studies reported adverse events [30–34]; Table 3 lists the most frequently observed grade 3 or 4 adverse events. The pooled results suggest that sorafenib induced a significantly higher rate of hand-foot syndrome (RR = 5.4, 95% CI: 1.8, 16.2; P = 0.003), diarrhea (RR = 1.45, 95% CI: 1.21, 2.34; P = 0.003), fatigue (RR = 1.70, 95% CI: 1.30, 2.23; P = 0.000), and rash (RR = 3.21, 95% CI: 1.65, 6.26; P = 0.001).

Table 1. Baseline characteristics of patients in the trials included in the meta-analysis.

| Author       | Treatment regimen | No. of patients | Median age (range) | Male/Female | Cause of disease (HBV/HCV/alcohol) | Child-Pugh Class (A/B) | ECOG PS (0/1/2) | BCLC stage (B/C) | MVI/EHS (present/absent) | Jadad score |
|--------------|-------------------|-----------------|--------------------|-------------|-----------------------------------|------------------------|----------------|-----------------|--------------------------|-------------|
| Brux J[9]    | sorafenib         | 301             | 67.5               | 179/122     | 32/86/79                          | 190/7                  | 113/84         | 40/157          | 133/64                    | 5           |
| placebo      |                    | 301             | 69.0               | 155/146     | 28/81/80                          | 187/2                  | 102/87         | 37/152          | 125/64                    |             |
| Cheng AL[10] | sorafenib         | 150             | 51(23–86)          | 127/23      | 106/16/0                          | 146/4                  | 38/104         | 7/143           | 54/96                     | 5           |
| placebo      |                    | 76              | 52(25–79)          | 66/10       | 59/3/0                            | 74/2                   | 21/51         | 3/73            | 26/50                     |             |
| Cheng AL[30] | sorafenib         | 544             | 59(18–84)          | 459/85      | 288/119/82                        | No report              | 288/254/2      | 89/454          | 415/129                    | 4           |
| placebo      |                    | 530             | 59(18–85)          | 436/94      | 290/113/91                        | No report              | 278/248/4      | 67/462          | 418/112                    |             |
| Abou-Alfa GK[31] | sorafenib      | 47              | 66(38–82)          | 31/16       | 3/10/no report                    | 47/0                   | 40/0/4         | No report        | No report                  | 4           |
| placebo      |                    | 49              | 65(38–81)          | 42/7        | 7/7/no report                     | 47/2                   | 41/0/3         | No report        | No report                  |             |
| Llovet JM[32] | sorafenib         | 299             | 64.9 ± 11.2        | 260/39      | 56/87/79                          | 284/14                 | 161/114        | 54/244          | 108/no report              | 5           |
| placebo      |                    | 303             | 66.3 ± 10.2        | 264/39      | 55/82/80                          | 297/6                  | 164/117        | 51/252          | 123/no report              |             |
| Johns-on PJ[33] | sorafenib      | 578             | 60(25–89)          | 484/94      | 258/119/83                        | 531/47                 | 352/226/0      | 97/449          | 158/420                    | 4           |
| Brivanib     |                    | 577             | 61(19–87)          | 483/94      | 254/116/106                       | 531/46                 | 361/216/0      | 95/444          | 155/422                    |             |
| Brivanib     | sunitinib         | 530             | 59(18–85)          | 436/94      | 290/113/91                        | No report              | 278/248/4      | 67/462          | 418/112                    |             |
| Rahaman OA[34] | sorafenib         | 26              | 53.5(33–75)        | No report   | 4/22                              | No report              | 8/18           | 0/14/12         | 10/16                     | 4           |
| capecitabine |                    | 26              | 59.5(42–70)        | No report   | 4/22                              | No report              | 0/13/13        | No report        | 7/19                      |             |

a, data from ECOG PS 1–2; b, data from ECOG PS 0–1; ECOG PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona Clinic Liver Cancer; MVI, macroscopic vascular invasion; EHS, extrahepatic spread; HBV, hepatitis B virus; HCV, hepatitis C virus.

doi:10.1371/journal.pone.0112530.t001
Discussion

The main aim of this meta-analysis was to assess the efficacy and safety of sorafenib in patients with advanced HCC. This meta-analysis suggests that while...
Figure 3. Comparison of sorafenib with other regimens for HCC patients in terms of time to progression (TTP).

doi:10.1371/journal.pone.0112530.g003

Figure 4. Comparison of sorafenib with other regimens for HCC patients in terms of overall response rate (ORR).

doi:10.1371/journal.pone.0112530.g004
sorafenib significantly improved OS (HR = 0.74, 95% CI: 0.61, 0.90; P = 0.002), and TTP (HR = 0.69, 95% CI: 0.55, 0.86; P = 0.001), it did not increase the ORR (RR = 0.85, 95% CI: 0.65, 1.11; P = 0.10). Moreover, upon subgroup analysis, sorafenib significantly prolonged TTP in patients, irrespective of MVI, EHS, and ECOGPS status. Similarly, an OS benefit was observed in patients with ECOG PS of 1–2 (HR = 0.58, 95% CI: 0.44, 0.75; P = 0.000), or MVI and/or EHS (HR = 0.62, 95% CI: 0.50, 0.77; P = 0.000).

There have been two published meta-analyses of sorafenib therapy for advanced HCC [35, 36]; this study expands on the prior meta-analyses in providing more significant evidence for the use of sorafenib in the treatment of advanced HCC. The larger sample size in our analysis provides a distinct advantage over previous reports in evaluating the efficacy of sorafenib. In addition, all the seven trials included are prospective, randomized controlled phase-3 clinical trials, whereas, in the meta-analysis conducted by Xin Zhang, et al. [35], of the six studies included, three were single-arm phase-2 trials. In order to include the three single-arm trials in the meta-analysis, the authors had introduced the control group from three RCTs as the control arm of these trials [35]; however, despite these modifications to the data from the three single-arm trials, the results revealed no change in the OS and TTP, and the final results may not be reliable. In the present meta-analysis, all included studies were well-designed and of high quality (Jadad score range from 4 to 5); the larger sample size and higher study quality have enabled more accurate and reliable statistical analyses. Furthermore, we also assessed the survival effect of sorafenib in special patients, including those with HBV-positive/negative, ECOG0/1–2, MVI and/or EHS present, normal/elevated AFP, which had not been discussed in the prior meta-analysis.

Among the disease etiologies for HCC, approximately 44% of the patients included in the study had chronic HCV infection, 38% had chronic HBV infection, and 14% suffered from alcohol abuse. It is assumed that chronic viral infections may induce HCC, through mechanisms that differ by specific virus and genotype [37]. Thus, we assume that patients with HBV- or HCV-induced HCC

| Adverse events       | Risk ratio (RR) | 95% CI     | P value |
|----------------------|----------------|------------|---------|
| Diarrhea             | 1.45           | 1.21–2.34  | 0.003   |
| Hand-foot syndrome   | 5.40           | 1.8–16.2   | 0.003   |
| Rash                 | 3.21           | 1.65–6.26  | 0.001   |
| Fatigue              | 1.70           | 1.30–2.23  | 0.000   |
| Hypertension         | 0.67           | 0.32–1.42  | 0.299   |
| Nausea               | 0.73           | 0.22–2.38  | 0.595   |
| Vomiting             | 0.57           | 0.19–1.68  | 0.308   |
| Neutropenia          | 0.28           | 0.02–3.60  | 0.328   |
| Leukopenia           | 0.82           | 0.004–164.09 | 0.942 |

These pooled results were calculated from the included studies of reference of 30–34.

doi:10.1371/journal.pone.0112530.t003
may respond differently to sorafenib treatment. However, in this meta-analysis, patients with both HBV-, and HCV-induced HCC did not receive any significant OS benefit from the sorafenib treatment. Contrary to our findings, in the SHARP trial [9], the authors found that patients with HCV-induced HCC had prolonged median OS (14.0 vs. 7.4 months, HR=0.50, 95% CI: 0.32, 0.77), whereas patients with HBV-induced HCC did not (HR=0.76, 95% CI: 0.38, 1.5). In another phase-3 clinical trial [33], the results were consistent with our findings, and neither of the HBV- or HCV- induced HCC patients received OS benefit upon treatment with sorafenib (for HBV-induced HCC, HR=0.98, 95% CI: 0.80, 1.19; for HCV-induced HCC, HR=1.33, 95% CI: 0.97, 1.83). However, considering that subgroup analysis was performed on only two phase-3 clinical trials for patients with HBV- or HCV- induced HCC, there is an urgent need for further investigation.

Tumor burden may be defined as MVI and EHS, which are both considered independent factors that affect the mortality of patients with HCC [38–40]. The presence of MVI and/or EHS limits the treatment options. For patients with MVI and/or EHS, curative treatment, which may include partial hepatectomy, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), and transcatheter arterial chemoembolization (TACE), is generally not recommended. In this study, sorafenib significantly prolonged both OS and TTP in patients with or without MVI and/or EHS, compared with other regimens.

In this meta-analysis, we found that the sorafenib-associated adverse events were consistent with those observed in previously published meta-analyses [35,36]. Grade 3 and 4 adverse events, including hand-foot syndrome (RR=5.40, 95% CI:1.8, 16.2; P=0.003), diarrhea (RR=1.45, 95% CI:1.21, 2.34; P=0.003), fatigue (RR=1.70, 95% CI:1.30, 2.23; P=0.000), and rash (RR=3.21, 95% CI:1.65, 6.26; P=0.001), were more commonly observed in the sorafenib group than in the control group. While the sorafenib-associated adverse events were mainly mild to moderate in severity [41], they may lead to dose reduction, or pause in sorafenib treatment. Another problem of note was the risk of hemorrhagic and cardiac events, which has been raised in previous studies [41,42].

This study had several limitations. First, our meta-analysis is based on seven RCTs; moreover, some of the trials had a relatively small sample size, which might lead to an overestimation of the treatment effect when compared with larger trials. Second, some of our subgroup analyses are based on only 2 to 3 studies; thus, the conclusions on sorafenib efficacy in specific cohorts should be interpreted with caution. Third, there was considerable heterogeneity among the studies, including differences in region, ethnicity, ECOG status, and viral etiology. These factors have the potential to affect our results. Finally, we tried to retrieve confidence intervals data from the investigators; however, this strategy was unsuccessful. Thus, we calculated the values of HRs with 95% CI derived from the Kaplan-Meier curves, which may lead to inaccurate data.

In summary, this study indicated that while sorafenib-therapy prolonged OS and TTP in the patients with advanced HCC, it did not increase ORR. Subgroup analysis showed that sorafenib was more effective in patients irrespective of ECOG
PS, or MVI and/or EHS. However, given the limited number of studies included, more prospective RCTs are warranted to evaluate these findings and investigate the efficacy of sorafenib in specific subpopulations of HCC patients.

Supporting Information

Checklist S1. PRISMA checklist. doi:10.1371/journal.pone.0112530.s001 (PDF)

Author Contributions

Conceived and designed the experiments: SP CD. Performed the experiments: SP YZ. Analyzed the data: FX CJ YX. Contributed reagents/materials/analysis tools: CD. Wrote the paper: SP. Reviewed the manuscript: CD.

References

1. Nordenstedt H, White DL, El-Serag HB (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42 Suppl 3: S206–S214.
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698–711.
3. Forner A, Llovet JM, Bruix J (2012) Hepatocellular carcinoma. Lancet 379: 1245–1255.
4. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362: 1907–1917.
5. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–7109.
6. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5: 835–844.
7. Adnane L, Trail PA, Taylor I, Wilhelm SM (2006) Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597–612.
8. Carломagno F, Anaganti S, Guida T, Salvatore G, Troncone G, et al. (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326–334.
9. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, et al. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57: 821–829.
10. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, et al. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer 48: 1452–1465.
11. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
12. Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135: 982–989.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
14. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.

16. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088–1101.

17. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.

18. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.

19. Pinter M, Sieghart W, Hucke F, Graziadei I, Vogel W, et al. (2011) Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 34: 949–959.

20. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, et al. (2011) Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54: 2055–2063.

21. Yang Y, Lu Y, Wang C, Bai W, Qu J, et al. (2012) Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys 63: 159–169.

22. Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, et al. (2013) Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol 30: 345.

23. Trojniak MP, Palozzo AC, Mazurek M, Jirillo A (2012) Sorafenib in hepatocellular carcinoma - a post marketing evaluation. Immunopharmacol Immunotoxicol 34: 419–422.

24. Song T, Zhang W, Wu Q, Kong D, Ma W (2011) A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastroenterol Hepatol 23: 1233–1238.

25. Balsom SM, Li X, Trolli E, Rose J, Bloomston M, et al. (2010) A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma. Oncology 78: 210–212.

26. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, et al. (2009) Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115: 428–436.

27. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293–4300.

28. Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, et al. (2010) Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 66: 837–844.

29. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, et al. (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47: 2117–2127.

30. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, et al. (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31: 4067–4075.

31. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, et al. (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304: 2154–2160.

32. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–390.

33. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, et al. (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31: 3517–3524.

34. Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, et al. (2013) Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 30: 655.

35. Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, et al. (2012) Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 11: 458–466.
36. Wang Z, Wu XL, Zeng WZ, Xu GS, Xu H, et al. (2013) Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev 14: 691–694.

37. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S35–S50.

38. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, et al. (1999) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29: 62–67.

39. (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: 751–755.

40. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329–338.

41. Wood LS (2006) Managing the side effects of sorafenib and sunitinib. Community Oncol 3: 558–562.

42. Semela D, Dufour JF (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41: 864–880.